Warwick researchers develop new vehicle for drug release

Published: 1-Feb-2011
Drug Delivery Research & Development Pharmaceutical

Plankton inspires creation of ‘stealth’ armour for slow release microscopic drug vehicles

Researchers at the University of Warwick in the UK have devised a simple way of giving drug-bearing polymer vesicles (microscopic polymer-based sacs of liquid) their own ‘armoured protection’ after being inspired by the ability of some forms of plankton and bacteria to build an extra natural layer of nanoparticle-like armour.

The scientists have been able to decorate these hollow structures with a variety of nanoparticles, opening a new strategy in the design of vehicles for drug release, for example by giving the vesicle ‘stealth’ capabilities which can avoid the body’s defences while releasing the drug.

Advances in polymerisation have boosted the creation of vesicles made from polymer molecules. Such vesicles have special chemical and physical properties, which make them potential drug delivery vehicles.

The University of Warwick team believed that more strength and tailored properties could be given to the vesicles if they could add an additional layer of colloidal ‘armour’ made from a variety of nanoparticles.

Lead researcher, Associate Professor Stefan Bon, said: ‘We took our inspiration from nature, in how it adds protection and mechanical strength in certain classes of cells and organisms. In addition to the mechanical strength provided by the cytoskeleton of the cell, plants, fungi, certain bacteria have an additional cell wall as outermost boundary.

‘Organisms that particularly attracted our interest were those with a cell wall composed of an armour of colloidal objects – for instance bacteria coated with S-layer proteins, or phytoplankton, such as the coccolithophorids, which have their own CaCO3-based nano-patterned colloidal armour.’

The Warwick researchers hit on a simple and effective method of adding different types of extra armour to the polymer-based vesicles. One example was a packed layer of microscopic polystyrene balls. Because the polystyrene balls had a crystalline-like ordered structure, the researchers could design a vesicle with an additional and precise permeable reinforced barrier for drug release.

The researchers used the same technique to add a gelatine-like polymer to provide ‘stealth’ armour to shield vesicles from unwanted attention from the body’s immune system while it slowly released its drug treatment.

This particular coating (a poly((ethyl acrylate)-co-(methacrylic acid)) hydrogel) absorbs so much surrounding water into its outer structure that it may be able to fool the body’s defence mechanism into believing it is in fact just water.

See more

You may also like

Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Read more
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche

Trending Articles

  1. Redefining safety, efficiency, and sustainability: SCHOTT Pharma launches next generation polymer syringe system A new cap design for prefillable polymer syringes provides tamper evidence at the individual syringe level, significantly reducing the risk of drug waste and ensuring patient safety. The integrated label concept, developed with Schreiner MediPharm, offers reliable first-opening indication, oxygen and light protection, and can include an RFID chip for accurate drug traceability and inventory management. A carton secondary packaging eliminates the need for blister packs, reducing waste and saving valuable storage space in hospitals and during transport, thereby cutting the carbon footprint of the entire value chain by up to 58%
  2. The IND advantage: why early derisking is a strategic imperative for complex biologics As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
  3. AI-designed drug product enters clinical development Phase I study of an AI-designed oral formulation sets a new standard in drug development

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

You may also like

Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Drug Delivery

Stevanato Group launches Deora pen injector platform targeting GLP-1 and incretin therapies

The fixed-dose, multi-use pull-push device accommodates volumes up to 0.75 mL, offering pharma partners a scalable, error-reducing delivery solution for diabetes and weight management programmes
Ingredients

Safe and accurate flow measurement for pharmaceutical production

Oval Gear (OG) meters from Titan Enterprises, fitted with a Namur sensor, provide consistent, accurate measurement across a wide range of liquids, from low-viscosity solvents to more viscous pharmaceutical ingredients
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

The path to commercial allogeneic iPSC therapies

The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development

Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies

Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Research & Development

Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation

New GS Ori‑Go vector technology supports titers higher than 11 g/L and reliable bulk pool stability, enabling more predictable material generation and shortened cell line development timelines
Subscribe now